This trial is evaluating whether rabbit antithymocyte globulin will improve 1 primary outcome and 6 secondary outcomes in patients with Rejection; Transplant, Kidney. Measurement will happen over the course of 12 months.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. Rabbit Antithymocyte Globulin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"While current research has established that rejection can be treated, no one is able to cure the problem of rejection. Because rejection occurs in all transplanted organs, it would be futile to attempt to cure it." - Anonymous Online Contributor
"There were more post-transplant kidney rejection incidents for each year, which might be caused by better maintenance and better surveillance of kidney transplant recipients. Furthermore, the increasing incidence of graft dysfunction and acute rejections might be caused by the development of acute rejection episodes following renal transplantation, whereas the incidence of chronic kidney rejection remains stable." - Anonymous Online Contributor
"There are many causes of rejection that can lead to chronic kidney diseases and an increasing incidence in older transplant recipients. Most individuals with chronic renal replacement therapies develop new diseases during the follow-up while the first diagnoses of these diseases are mostly present in the early period after transplantation." - Anonymous Online Contributor
"Rejection is a serious side effect of renal transplantation. It can be severe and life-threatening. Transplantation for this serious disease is a life-saving alternative to an unrelated donor." - Anonymous Online Contributor
"Rejections are not always associated with a specific treatment. A person's doctor will usually ask if they are taking any kind of immunosuppressant, when exactly the rejection is happening, and if a transplant is contemplated." - Anonymous Online Contributor
"The most common presentations of [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant) rejection were cough suggestive of bronchiolitis obliterans, fever, and muscle acetic pains. Patients with mycotic or fungal rejection were usually afebrile but with mycotic symptoms whereas in patients with antibody-mediated rejection fever was usually the only sign, accompanied by a mycotic rash. In each presentation there were multiple causes for symptoms and the mainstay of treatment involved the cessation of high-dose immunosuppression and the introduction of specific immune-suppressing drugs." - Anonymous Online Contributor
"The application of RANTES-Fc fusion protein of rabbit IgG2a in conjunction with RANTES-Fc can provide satisfactory immuno-compromised rabbit for therapeutic purposes in comparison with RANTES, as well as a strategy that can be employed in animal model." - Anonymous Online Contributor
"This review shows that the risk of transplant rejection does not run in families. Results from a recent paper does have some weaknesses, though. There are only three families included in the series but only a small number of families would be necessary to confirm the result of the present study. It does not seem likely that one of the families would have been selected for this case series if there really are no risk factors for transplant rejection. Further prospective studies with a larger sample size are needed." - Anonymous Online Contributor
"Findings from a recent study suggest that the treatment with RATG, either by high doses given in the first week after [transplant](https://www.withpower.com/clinical-trials/transplant)ation or alternatively by repeated low doses in the course of graft rejection after 6 months post-transplantation, has no clinically relevant effect on the time to hematopoietic reconstitution. The possibility that RATG modulates the proliferation of T lymphocytes and granulocytes cannot be excluded in some patients. Nevertheless, the fact that a high-dose regimen (≤150 mg/m2) is associated with a higher frequency of infections and rejection suggests that it should be used carefully in all patients." - Anonymous Online Contributor
"There is currently no reliable evidence to support the use of RATG in human solid organ rejection. It is only used in an investigational setting by small-centre clinicians who are skilled in its use. Its use is not supported by evidence or practice guidelines and it is not routinely included in drug formulary listing by major healthcare organisations." - Anonymous Online Contributor
"RATG induction therapy rarely produces serious side effects in clinical settings. Mild and/or temporary side effects are commonly reported during the 2 week infusion period. Most patients tolerated these adverse events and tolerated the drug once the infusion was stopped." - Anonymous Online Contributor
"Rejection is the major cause of failure after [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant)ation. However, the exact cause of rejection is unknown. Because we didn't use immunosuppressive agents, the precise cause of rejection may have been from both the disease itself and from the immunosuppressive therapy. We found that the underlying cause is related to the kidney's immune system and the patient's immune reaction to the transplanted organ. The most important and unexpected results of this study seem to have been the higher likelihood of primary graft nonfunction after kidney transplantation if the patient has active systemic lupus erythematosus and if a woman smokes." - Anonymous Online Contributor